Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.
[allergic bronchopulmonary aspergillosis]
Systemic
administration
of
mesenchymal
stromal
cells
(
MSCs
)
suppresses
airway
inflammation
and
methacholine-induced
airway
hyper-responsiveness
(
AHR
)
in
mouse
models
of
T
helper
cell
(
Th
)
type
2
-
mediated
eosinophilic
allergic
airway
inflammation
(
AAI
)
;
however
,
the
efficacy
of
MSCs
in
mouse
models
of
severe
Th
17
-
mediated
neutrophilic
AAI
has
not
yet
been
demonstrated
.
We
assessed
MSC
effects
in
a
mouse
model
of
mixed
Th
2
/
Th
17
AAI
produced
by
mucosal
exposure
to
Aspergillus
fumigatus
hyphal
extract
(
AHE
)
.
Following
sensitization
produced
by
oropharyngeal
AHE
administration
,
systemic
(
tail
vein
)
administration
of
syngeneic
MSCs
on
the
first
day
of
challenge
significantly
reduced
acute
AHR
predominantly
through
reduction
of
Th
17
-
mediated
airway
inflammation
.
In
parallel
experiments
,
MSCs
also
mitigated
AHR
when
administered
during
recurrent
challenge
10
weeks
after
initial
sensitization
and
challenge
through
reduction
in
systemic
Th
17
-
mediated
inflammation
.
Investigation
into
potential
mechanistic
actions
of
MSCs
in
this
model
demonstrated
that
although
T
regulatory
cells
were
increased
in
all
AHE-treated
mice
,
MSC
administration
did
not
alter
T
regulatory
cell
numbers
in
either
the
acute
or
recurrent
model
.
Differential
induction
of
interleukin-
17
a
secretion
was
observed
in
ex
vivo
restimulation
of
mediastinal
lymph
node
mixed
-cell
cytokine
analyses
.
Although
the
mechanisms
by
which
MSCs
act
to
decrease
inflammation
and
AHR
in
this
model
are
not
yet
fully
elucidated
,
decrease
in
Th
17
-
mediated
airway
inflammation
appears
to
play
a
significant
role
.
These
results
provide
a
basis
for
further
investigations
of
MSC
administration
as
a
potential
therapeutic
approach
for
severe
refractory
neutrophilic
asthma
.
Diseases
Validation
Diseases presenting
"potential therapeutic approach"
symptom
allergic bronchopulmonary aspergillosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom